Ipsen Biopharmaceuticals, Inc.
1 Main Street
Unit 700
Cambridge
MA
02142
United States
Tel: 617-679-8500
Website: https://www.ipsenus.com/
Email: talentacquisition@ipsen.com
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
557 articles with Ipsen Biopharmaceuticals, Inc.
-
Ipsen will seek a new approval for Onivyde as a treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC) after posting positive Phase III progression survival data.
-
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
11/9/2022
Ipsen announced the Phase III NAPOLI 3 trial of Onivyde® plus 5 fluorouracil/leucovorin and oxaliplatin met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma and key secondary efficacy outcome of progression-free survival also showed significant improvement over the comparator arm.
-
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
10/27/2022
Ipsen, a global specialty-driven biopharmaceutical company, presents its sales performance for the year to date and the third quarter of 2022.
-
Ipsen hit another stumbling block in its bid for an FOP approval as the FDA's Endocrinologic and Metabolic Drugs Advisory Committee postponed its meeting on the NDA for palovarotene capsules.
-
Theratechnologies’ Trogarzo for HIV, Alnylam’s Lumasiran for advanced primary hyperoxaluria, scPharmaceuticals' Furoscix for heart failure and more. Here's a look at the FDA's October calendar.
-
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
8/3/2022
Ipsen announced that the Phase III RESILIENT trial did not meet its primary endpoint of overall survival compared to topotecan.
-
Ipsen said that Onivyde did not show greater benefit than topotecan used in patients with SCLC who have progressed on or after platinum-based first-line therapy treatment.
-
Marengo Therapeutics and Ipsen have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.
-
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic
8/1/2022
Ipsen and Marengo Therapeutics, Inc. announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic.
-
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance
7/28/2022
Ipsen, a global specialty-driven biopharmaceutical company, presents its financial results for the first half of 2022: H1 2022 financial results Strong sales growth of 10.5% at CER1 Core operating margin of 39.6%; IFRS operating margin of 35.7% Core consolidated net profit of €420m, growing by 19.9%.
-
Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission
6/29/2022
Ipsen announced that the U.S. Food and Drug Administration has accepted for Priority Review its resubmitted New Drug Application for investigational palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder.
-
Ipsen announced it is acquiring the company and its cancer drugs, including Tazverik, which were approved for two different indications by the FDA in 2020.
-
Ipsen to acquire Epizyme, expanding its portfolio in oncology
6/27/2022
Ipsen and Epizyme announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme.
-
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury
6/9/2022
Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen announced that Dysport® has received positive opinion in Europe for the management of urinary incontinence in adults with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis, who are regularly performing clean intermittent catheterization.
-
Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
5/26/2022
Regulatory News: Ipsen announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor, Cabometyx®, across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting to be held on 3-7 June.
-
Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
5/3/2022
Ipsen announced that the European Commission has approved the use of Cabometyx® as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.
-
Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022
4/27/2022
Ipsen, a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2022.
-
Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) Designed to Improve Patient Experience
3/16/2022
Ipsen announced it will invest in a new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot, to deliver further innovation in the class with the aim of improving administration and the injection experience for patients.
-
Ipsen: New Patient-Reported Data Demonstrated High Satisfaction Levels and Fewer Patients Reporting Injection-site Pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide)
3/8/2022
Ipsen published new data from seven abstracts to be presented at the hybrid-setting 19th Annual European Neuroendocrine Tumor Society Conference, 10-11 March 2022, in Barcelona, Spain.
-
Ipsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER Trial
2/15/2022
Ipsen announced two-year follow-up results from analyses of the Phase III CheckMate -9ER trial, which demonstrated sustained survival and response rate benefits 1, as well as health-related quality of life improvements 2, with the combination of Cabometyx® and Opdivo® versus sunitinib in the first-line treatment of advanced renal cell carcinoma.